Zimbabwe has declined a major US health deal worth 367 million US dollars (£272m) spanning five years over Washington's insistence on confidential biological samples.
The decision was revealed following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman later clarified that the US was seeking health data for scientific study and profit while was not willing to guarantee the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further talks to reach a agreement acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Context
This rejection comes after a comparable situation in Kenya, where a high court halted a related deal with the US following legal challenges were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral agreements to boost openness and responsibility.
As per statements, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our country would provide the raw materials for medical research without any assurance that the final treatments would be accessible to our citizens if a future pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were disrupting systems already established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This framework is intended to guarantee that when a nation contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We welcome further dialogue with our US partners on how subsequent co-operation could be structured in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that talks need to persist since a large portion of the nation's Aids initiatives were funded by foreign aid.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
The situation underscores the continuing debate between accepting much-needed international aid and safeguarding national sovereignty in an increasingly data-driven world.